BOSTON--(BUSINESS WIRE)--Jul. 2, 2018--
Verastem, Inc. (NASDAQ:VSTM) (Verastem Oncology or the Company), focused
on developing and commercializing medicines to improve the survival and
quality of life of cancer patients, today announced that the Company
will participate in the Oppenheimer Boston Oncology Insight Summit on
July 10-11, 2018, in Boston, Massachusetts. The two-day event will
feature oncology-focused companies and will consist of one-on-one
meetings with institutional investors preceded by a Lecture Series from
members of the Whitehead Institute in Cambridge, Massachusetts.
Members of Verastem Oncology’s executive team will participate in the
event. To learn more about the event please visit the following link: https://www.opco.com/conferences/oncology18/index.aspx.
About Verastem Oncology
Verastem, Inc. (Nasdaq:VSTM), operating as Verastem Oncology, is a
biopharmaceutical company focused on developing and commercializing
medicines to improve the survival and quality of life of cancer
patients. Verastem Oncology is currently developing duvelisib, a dual
inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma,
which has successfully met its primary endpoint in a Phase 2 study in
indolent Non-Hodgkin Lymphoma (iNHL) and a Phase 3 clinical trial in
patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL). Verastem Oncology’s New Drug Application (NDA) requesting the
full approval of duvelisib for the treatment of patients with relapsed
or refractory CLL/SLL, and accelerated approval for the treatment of
patients with relapsed or refractory follicular lymphoma (FL) was
accepted for filing by the U.S. Food and Drug Administration (FDA),
granted Priority Review and assigned a target action date of October 5,
2018. In addition, Verastem Oncology is developing the focal adhesion
kinase (FAK) inhibitor defactinib, which is currently being evaluated in
three separate clinical collaborations in combination with
immunotherapeutic agents for the treatment of several different cancer
types, including pancreatic cancer, ovarian cancer, non-small-cell lung
cancer (NSCLC), and mesothelioma. Verastem Oncology’s product candidates
seek to treat cancer by modulating the local tumor microenvironment and
enhancing anti-tumor immunity. For more information, please visit www.verastem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180702005288/en/
Source: Verastem, Inc.
Verastem Oncology, Inc.
Marianne M. Lambertson,
Vice President, Corporate Communications